JP7669113B2 - トランスフェリン受容体トランスジェニックモデル - Google Patents

トランスフェリン受容体トランスジェニックモデル Download PDF

Info

Publication number
JP7669113B2
JP7669113B2 JP2019545322A JP2019545322A JP7669113B2 JP 7669113 B2 JP7669113 B2 JP 7669113B2 JP 2019545322 A JP2019545322 A JP 2019545322A JP 2019545322 A JP2019545322 A JP 2019545322A JP 7669113 B2 JP7669113 B2 JP 7669113B2
Authority
JP
Japan
Prior art keywords
tfr
mouse
seq
rat
apical domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019545322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510418A (ja
JP2020510418A5 (enExample
Inventor
マーク エス． デニス
アダム ピー． シルバーマン
ジョイ ユ ズチェロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2020510418A publication Critical patent/JP2020510418A/ja
Publication of JP2020510418A5 publication Critical patent/JP2020510418A5/ja
Priority to JP2023085382A priority Critical patent/JP2023116513A/ja
Priority to JP2025036281A priority patent/JP2025087857A/ja
Application granted granted Critical
Publication of JP7669113B2 publication Critical patent/JP7669113B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019545322A 2017-02-17 2018-02-15 トランスフェリン受容体トランスジェニックモデル Active JP7669113B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023085382A JP2023116513A (ja) 2017-02-17 2023-05-24 トランスフェリン受容体トランスジェニックモデル
JP2025036281A JP2025087857A (ja) 2017-02-17 2025-03-07 トランスフェリン受容体トランスジェニックモデル

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762460692P 2017-02-17 2017-02-17
US62/460,692 2017-02-17
US201762543559P 2017-08-10 2017-08-10
US201762543658P 2017-08-10 2017-08-10
US62/543,559 2017-08-10
US62/543,658 2017-08-10
US201762583314P 2017-11-08 2017-11-08
US62/583,314 2017-11-08
PCT/US2018/018302 WO2018152285A1 (en) 2017-02-17 2018-02-15 Transferrin receptor transgenic models

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023085382A Division JP2023116513A (ja) 2017-02-17 2023-05-24 トランスフェリン受容体トランスジェニックモデル

Publications (3)

Publication Number Publication Date
JP2020510418A JP2020510418A (ja) 2020-04-09
JP2020510418A5 JP2020510418A5 (enExample) 2021-03-11
JP7669113B2 true JP7669113B2 (ja) 2025-04-28

Family

ID=61628463

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019545322A Active JP7669113B2 (ja) 2017-02-17 2018-02-15 トランスフェリン受容体トランスジェニックモデル
JP2023085382A Pending JP2023116513A (ja) 2017-02-17 2023-05-24 トランスフェリン受容体トランスジェニックモデル
JP2025036281A Pending JP2025087857A (ja) 2017-02-17 2025-03-07 トランスフェリン受容体トランスジェニックモデル

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023085382A Pending JP2023116513A (ja) 2017-02-17 2023-05-24 トランスフェリン受容体トランスジェニックモデル
JP2025036281A Pending JP2025087857A (ja) 2017-02-17 2025-03-07 トランスフェリン受容体トランスジェニックモデル

Country Status (9)

Country Link
EP (2) EP4628586A2 (enExample)
JP (3) JP7669113B2 (enExample)
KR (1) KR102637590B1 (enExample)
CN (1) CN110382526B (enExample)
AU (1) AU2018221704B2 (enExample)
CA (1) CA3053370A1 (enExample)
IL (1) IL268659A (enExample)
SG (1) SG11201907419PA (enExample)
WO (1) WO2018152285A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
SG11202011743SA (en) 2018-06-18 2021-01-28 Denali Therapeutics Inc Fusion proteins comprising progranulin
WO2021133907A1 (en) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Progranulin variants
CN112243953B (zh) * 2020-07-15 2022-02-11 吉林医药学院 TfR1肺组织特异性敲除小鼠模型及其构建方法和应用
PE20231931A1 (es) 2020-10-14 2023-12-01 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas
CN112501124A (zh) * 2020-11-27 2021-03-16 领诺(上海)医药科技有限公司 稳定表达人转铁蛋白受体1细胞株的制备方法及其应用
EP4370539A4 (en) * 2021-07-16 2025-05-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric tfr1
US20250136963A1 (en) 2021-12-17 2025-05-01 Denali Therapeutics Inc. Fusion proteins comprising alpha-l-iduronidase enzymes and methods
CA3242959A1 (en) 2021-12-17 2025-02-26 Denali Therapeutics Inc POLYPEPTIDE ENGINEERING, LIBRARIES AND ENGINEERED POLYPEPTIDES FOR CD98 HEAVY CHAIN LINK AND TRANSFERRINE RECEIVER
US20250215077A1 (en) 2022-03-28 2025-07-03 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
KR20250048010A (ko) * 2022-07-29 2025-04-07 리제너론 파마슈티칼스 인코포레이티드 변형된 트랜스페린 수용체 좌위를 포함하는 비-인간 동물
EP4658684A1 (en) 2023-01-30 2025-12-10 ISAR Bioscience GmbH Human anti-trem2 antibody for treating neurodegenerative disorders
CN116784280B (zh) * 2023-08-10 2025-08-19 广东药康生物科技有限公司 一种tfrc人源化小鼠模型的构建方法及其应用
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898094A (en) 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
US6175057B1 (en) 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
EP1620564A4 (en) * 2003-04-18 2008-03-12 Cytovia Inc METHODS FOR TREATING DISEASES INDUCING APOPTOSIS INDUCTION AND SCREENING ASSAYS
WO2009131632A1 (en) 2008-04-14 2009-10-29 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
WO2011100058A1 (en) 2010-02-09 2011-08-18 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US8476485B2 (en) 2010-06-24 2013-07-02 Academia Sinica Non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function
US9232775B2 (en) 2012-08-03 2016-01-12 Industry-Academic Cooperation Foundation, Yonsei University Genetically engineered mouse model for autism spectrum disorder having deletion of Shank2 gene and use thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP2016516399A (ja) 2013-03-13 2016-06-09 オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション 非機能性ｔｓｐｏ遺伝子を有するトランスジェニック非ヒト生物
EP3988649B1 (en) 2013-09-18 2024-11-27 Kymab Limited Methods, cells and organisms
CN103897033A (zh) * 2014-03-31 2014-07-02 中国药科大学 转铁蛋白受体TfR特异性结合肽及其应用
CN107531788B (zh) * 2015-06-24 2022-06-21 豪夫迈·罗氏有限公司 对her2和血脑屏障受体特异性的三特异性抗体及使用方法
CA3053381A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Virol.，2012，vol. 86, no. 7，pp.4024-4028
SCIENCE TRANSLATIONAL MEDICINE, (2014), VOL:6, PAGE(S):261RA154 (1-10)

Also Published As

Publication number Publication date
KR20190135993A (ko) 2019-12-09
JP2020510418A (ja) 2020-04-09
WO2018152285A1 (en) 2018-08-23
SG11201907419PA (en) 2019-09-27
EP3583118C0 (en) 2025-06-11
EP4628586A2 (en) 2025-10-08
EP3583118B1 (en) 2025-06-11
CA3053370A1 (en) 2018-08-23
IL268659A (en) 2019-10-31
CN110382526B (zh) 2023-12-26
CN110382526A (zh) 2019-10-25
JP2023116513A (ja) 2023-08-22
EP3583118A1 (en) 2019-12-25
AU2018221704A1 (en) 2019-09-19
JP2025087857A (ja) 2025-06-10
AU2018221704B2 (en) 2021-08-19
KR102637590B1 (ko) 2024-02-15

Similar Documents

Publication Publication Date Title
JP7669113B2 (ja) トランスフェリン受容体トランスジェニックモデル
US11612150B2 (en) Transferrin receptor transgenic models
Montoyo et al. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice
JP6443811B2 (ja) Ｍｒａｐ２ノックアウト
JP3981416B2 (ja) Ｐｃａ３タンパク質、ｐｃａ３遺伝子、及びこれらの用途
JP2000157286A (ja) アミノ酸輸送蛋白及びその遺伝子
IL271073B1 (en) B4galt1 variants and uses thereof
WO2022057903A1 (en) Genetically modified non-human animal with human or chimeric glp1r
HU228779B1 (en) Novel organic anion transport proteins
US20220017964A1 (en) Cornulin (CRNN) Variants And Uses Thereof
CN114747541A (zh) 一种psgl-1人源化非人类动物模型的构建方法及应用
KR20250122512A (ko) Cd98 중쇄 형질전환 모델
US5712148A (en) DNA encoding a human betaine/GABA transporter and uses thereof
JP2025541318A (ja) Ｃｄ９８重鎖トランスジェニックモデル
US20090083866A1 (en) Transgenic rosa26-luciferase mice for bioluminescent imaging
Kozar Role of Adam23 and Lgi proteins in functional organisation of Kv1 channels in myelinated axons
CN120112164A (zh) 包含修饰的转铁蛋白受体基因座的非人动物
Khalaj Identification and Characterization of Two Orphan Proteins as Novel Cis-ligands of Neurexin Complexes
CN113999873A (zh) 一种基因修饰的非人动物的构建方法及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230627

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230705

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250416

R150 Certificate of patent or registration of utility model

Ref document number: 7669113

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150